[General hyperthermia in the chemoradiotherapy of small-cell lung cancer].
Treatment results were compared in 2 groups of patients with advanced small-cell lung cancer. Group 1 (52 cases) received chemoradiation treatment alone whereas in group 2 (41 patients) it was combined with general hyperthermia (temperature 40-41.8 degrees C during 3-4 hours). Response was observed in 63.5% of patients of group 1 and 79.5% of those in group 2. Complete response rates did not differ significantly (23.1 and 28.2%, respectively). 40.6 +/- 8.2% of patients receiving chemoradiation treatment plus general hyperthermia survived over 1 year, 20.5 +/- 7.1%--over 1.5 years and 15.9 +/- 6.7%--over 2 years. In the control group, the respective rates were 22.2 +/- 5.8%, 5.1 +/- 3.4% and 5.1 +/- 3.4%.
Zhavrid
E A
EA
Sachivko
N V
NV
Fradkin
S Z
SZ
Rud'ko
A S
AS
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000401:mortality / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D008175:Lung Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011879:Radiotherapy Dosage; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D008727:Methotrexate
Obshchaia gipertermiia pri khimioluchevoĭ terapii melkokletochnogo raka legkogo.